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INTRODUCTION
Despite causing over half a million deaths
per year, cancer continues to elude our
understanding and evade our therapeutic
approaches. Our comprehension of can-
cer metabolism lags woefully behind other
areas of cancer research. Starting with the
seminal experiments done in the 1920s
by the Cori’s and Warburg (1, 2), tumors
are often described as being glucose avid
tissues that produce lactate despite ade-
quate oxygen (O2) tension (i.e., the “War-
burg Effect”). Only recently, we have begun
to understand that tumor cell metabolism
is significantly more complicated. Specif-
ically, insight from the study of lactate
metabolism has shed light on the pecu-
liar metabolic nature of tumor cells. Here,
we present a brief overview of some of the
recent developments in the ever expand-
ing literature on lactate metabolism and
cancer.
LACTATE METABOLISM
First discovered in 1780 by Carl Wilhelm
Scheele, lactate was found to be elevated in
the muscles of hunted stags in 1808 (3).
Later, experiments by Pasteur (4), Meyer-
hof (5), and A.V. Hill (6) led to widespread
understanding of the glycolytic pathway
and the notion that lack of O2 led to fer-
mentation and lactate accumulation. Out
of this early work grew the idea that lac-
tate was a waste that must be cleared from
the muscles and blood, preferably by being
converted to glucose in the liver via the
Cori cycle. However,over the last 50 years, it
has been demonstrated in numerous exper-
iments that lactate is both a potent fuel
and signaling molecule, and it is constantly
being produced and circulated through-
out the body, often when there is adequate
O2 (7). Despite this evidence, lactate as a
“hypoxic waste product” is still erroneously
taught in many medical schools to this day.
While lack of adequate O2 forbids the
continuation of oxidative phosphorylation,
the notion that lactate production was
solely the result of inadequate O2 began
to change in the 1960s. In a series of ele-
gant experiments in dog muscle, Wendell
Stainsby’s group provided evidence that
the lactate-releasing canine muscle was not
dysoxic (8). Despite criticism over some of
his techniques the concept proved correct:
lactate formation due to lack of O2 is often
the exception rather than the rule, even
in critically ill patients. The lactate dehy-
drogenase (LDH) reaction is a rapid, near-
equilibrium reaction that lies heavily in the
direction of lactate; any time glycolysis is
active, lactate is formed and equilibrates
with local lactate gradients. Lactate equi-
librates mainly by diffusing across mem-
branes via monocarboxylate transporters
(MCTs). In lactate-producing tissues or sit-
uations, this often means exporting lactate
into circulation, where both local and dis-
tant tissues can take it up and use it as a
fuel.
This observation that lactate is con-
stantly being produced and consumed
formed the basis of the cell-to-cell lactate
shuttle, a hypothesis originally introduced
by George Brooks in 1984 (9). His widely
accepted hypothesis posits that lactate is
the key intermediate metabolite in whole
body metabolism. It is well described in
the literature that lactate can readily replace
glucose as a fuel for almost all cells of the
body (any cell with mitochondria), includ-
ing heart, liver, muscle, and even brain (10).
So well-supported in so many different
experimental settings is his hypothesis that
it can now firmly be called “Lactate Shuttle
Theory”(11). Finally, more recent work has
shown that lactate is also a potent signal-
ing molecule, triggering the stabilization
of hypoxia inducible factor-1α (HIF-1α),
and subsequently increasing expression of
vascular endothelial growth factor (VEGF),
resulting in angiogenesis (Figure 1). This
new understanding is only now beginning
to be explored in tumor models (see Lac-
tate and Cancer: Convergence and Recent
Studies below).
TUMOR METABOLISM
Unlike lactate metabolism, the study of
tumors dates back to as long ago as 1600
BC with descriptions of breast masses (12).
However, the modern era of tumor metab-
olism began in the 1920s with experiments
by the Cori’s and Otto Warburg (1, 2).
Briefly, the Cori’s showed that the axil-
lary vein draining a hen wing with a sar-
coma had a higher lactate and lower glu-
cose when compared to the non-tumor
limb. Taking a similar approach, War-
burg et al. (2) measured arteriovenous (a–
v) differences across tumor beds in rat
tumor models. He showed that the vein
always had more lactate and less glucose
than the artery feeding the tumor, sug-
gesting a net lactate output in presumably
normoxic tumor beds. These early inves-
tigators clearly recognized the “Warburg
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FIGURE 1 | Lactate metabolism in tumors: a simplified cartoon
showing lactate being shuttled to and from cancer cells and its
potential role as a signaling molecule in driving angiogenesis.
Increasing pyruvate inhibits formation of 2-oxoglutarate, with the net effect
of less degradation of HIF-1α in the proteasome and increased VEGF and
angiogenesis. Note that pyruvate can be increased by hypoxia “backing up”
theTCA cycle, or by importation of lactate via MCT1s. Some lactate
shuttling likely is present between cancer cells and (1) other cancer cells
within the tumor, (2) tumor stromal cells, and/or (3) non-tumor cells both
local and distant from the tumor. Note that the traditional “Warburg Effect”
describes tumors relying heavily on glucose uptake (via GLUTs) with
subsequent lactate exportation (via MCT4s) in normoxia. A “Reverse
Warburg Effect” describes lactate production from stromal cells, which is
then taken up and used by local cancer cells. Some unique combination of
these pathways is likely present within each tumor, highlighting the need for
further in vivo experimentation. (Note that MCTs can transport lactate either
direction; MCT1s are typically expressed in cells importing lactate, while
MCT4s are expressed in cells exporting lactate.)
Effect,” the “unusual” behavior whereby
tumors produce lactate in a normoxic
environment.
Do all tumors exhibit the Warburg
Effect? In the current era of genomics
and the understanding that cancer repre-
sents hundreds or thousands of different
genotypes, it seems unlikely that all tumor
cells would behave in an identical manner.
Even in cells of the same clonal expan-
sion, the metabolism of any one cell will
vary depending on its local microenviron-
ment. For example, cancer cells at a hypoxic
core might use glucose and produce lac-
tate, while cells on the periphery, close to a
robust vascular and O2 supply, might take
up this lactate and oxidize it as a fuel. This
concept of shuttling lactate between cancer
cells was first introduced by Sonveaux et al.
(13). A similar case has been made for a
“Reverse Warburg” effect, whereby stromal
cells are proposed to produce lactate that
tumor cells then take up and oxidize (14).
LACTATE AND CANCER: CONVERGENCE
AND RECENT STUDIES
In an insightful commentary on the work
done by Sonveaux et al. (13), Semenza
poignantly questioned, “Was there any
precedent that should have alerted us to
this symbiotic relationship between aero-
bic and hypoxic cancer cells? Of course: the
well known recycling of lactate in exercis-
ing muscle” (15). Cancer cell metabolism
has long been investigated in cultured cells
in vitro, typically with non-physiological
conditions (e.g., media with 25 mM glu-
cose instead of 5 mM for cells that have
been passaged many times) that hinder
translation to therapeutic models. While
great insight can be gained from experi-
ments in vitro, it is critical that studies also
examine tumors in the context of their local
microenvironment. We propose that more
studies of animal tumor models in vivo
are needed to bridge the current gap from
bench to bedside.
While one can debate which cells may
or may not exhibit a Warburg Effect (16), it
is clear that many tumors are glucose avid
[the basis of positron emission tomogra-
phy (PET) scans] and subsequently pro-
duce lactate. In a provocative piece in
2009, Nijsten and van Dam (17) presented
a hypothetical treatment whereby glucose
might be systemically lowered and lac-
tate provided exogenously. If tumors are
glucose consumers/lactate producers and
almost all other tissues in the body can
actively take up and use lactate as a fuel,
why not systemically induce hypoglycemia
to starve tumor cells while providing lac-
tate as a salvage fuel for other tissues?
While the idea of inducing hypoglycemia
in vivo in this manner seems daunting,
proof of concept for this idea came from
a recent case report out of their hospi-
tal (18). This case reports on a patient
who walked into the emergency depart-
ment with extreme hypoglycemia [(glu-
cose)= 13 mg/dL). Not only was he neither
comatose nor dead but also was he alert and
oriented. Upon first sampling, his blood
lactate was 25 mM, likely serving as a sal-
vage fuel for his vital organs, particularly
his brain. Work to investigate this con-
cept of a “lactate-protected hypoglycemia”
should be pursued.
Finally, lactate also has a role as a potent
signaling molecule. This is of particular
interest in tumor metabolism, as high-
lactate levels are often associated with a
worse prognosis [e.g., Ref. (19)]. One pro-
posed mechanism for this poor prognosis
is increased angiogenesis. Any change in
lactate immediately equilibrates with pyru-
vate through LDH and vice versa. Accu-
mulating pyruvate inhibits the formation
of 2-oxoglutarate, the molecule responsi-
ble for targeting HIF-1α for degradation in
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the proteasome. When lactate (pyruvate)
levels increase, HIF-1α drives angiogenesis
via VEGF expression. It should be empha-
sized that HIF-1α stabilization can be dri-
ven by lactate or hypoxia independently
(Figure 1).
This lactate-to-VEGF pathway has been
shown to be independent of O2 ten-
sion and appears to be an appealing tar-
get for potential anti-tumor therapies. De
Saedeleer et al. (20) showed that oxida-
tive tumor cells in vitro activate HIF-1α
via importation of lactate. In another study
in glycolytic glioma tumor cells in vitro,
lactate exposure increased HIF-1α levels
independent of hypoxia (21); in a similar
study in vivo (mice), intraperitoneal lac-
tate administration enhanced xenografted
tumor growth, metastasis, and vascular-
ity (22). Finally, another group inhibited
MCTs in Lewis Lung carcinoma mice, dri-
ving a twofold reduction in vascularity in
<2 weeks (13).
In an effort to understand the role of
lactate in the tumor microenvironment,
the KB Jones Lab at Utah introduced
a new transgenic mouse model [alveo-
lar soft parts sarcoma (ASPS)]. In this
model, the ASPS oncogene was bred into
mice that subsequently developed tumors
that were indistinguishable histologically
from human ASPS tumors. These vas-
cular tumors had high levels of HIF-
1α despite being normoxic throughout.
Remarkably, these tumors demonstrated
a dramatic increase in vascularity when
the mice were given daily intraperitoneal
injections of lactate for 2 weeks. Perhaps
most interesting was the finding that these
tumors formed only within the cranial
vault in mice, which was also the area




Current understandings of lactate and
tumor metabolism are now converging,
seemingly providing as many questions
as answers. Lactate is both a potent fuel
(oxidative) and signaling molecule (angio-
genesis) in most tissues throughout the
body. Early work in tumor models suggests
that lactate may be either generated and
exported or imported and used as a fuel
and potent signaling molecule. Lactate-
protected hypoglycemia may be a viable
strategy in tumors that exhibit a “War-
burg Effect,” while MCT inhibitors may be
useful in tumors whose angiogenesis is dri-
ven by lactate (e.g., ASPS). Most tumors
likely lie somewhere between these two
extremes, and either or both may soon
serve as important adjuvant therapies. It
is critical that more studies investigate the
metabolic behavior of specific tumors with
models in vivo. Only when we understand
the metabolic behavior of tumors in vivo
can we then begin to understand how to
effectively target them therapeutically.
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